StockData
Provectus Biopharmaceuticals, Inc. logo

Provectus Biopharmaceuticals, Inc. (PVCT) stock

PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$0.05+0.00 (+0.39%)

Close on Oct 19, 2026Market cap $20.55MP/E –Yield –

Provectus Biopharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Provectus Biopharmaceuticals's revenue for the twelve months ending Dec 31, 2025 was $336.11K, down 45.5% year over year. For fiscal 2025 it was $336.11K, down 45.5% from the year before. The highest annual figure on record is $989.04K in fiscal 2022.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$336.11K-45.5%
FY2024Dec 31, 2024$617.14K+10.7%
FY2023Dec 31, 2023$557.71K-43.6%
FY2022Dec 31, 2022$989.04K–
FY2015Dec 31, 2015$0–
FY2014Dec 31, 2014$0–
FY2013Dec 31, 2013$0–
FY2012Dec 31, 2012$0–
FY2011Dec 31, 2011$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$0-100.0%
Q2 FY2025Jun 30, 2025$57.48K-77.5%
Q1 FY2025Mar 31, 2025$278.63K+17.0%
Q4 FY2024Dec 31, 2024$14.33K-88.2%
Q3 FY2024Sep 30, 2024$109.75K+57.4%
Q2 FY2024Jun 30, 2024$254.99K+57.6%
Q1 FY2024Mar 31, 2024$238.07K+16.1%
Q4 FY2023Dec 31, 2023$121.11K-26.5%
Q3 FY2023Sep 30, 2023$69.73K-77.9%
Q2 FY2023Jun 30, 2023$161.84K-49.7%
Q1 FY2023Mar 31, 2023$205.03K+9.3%
Q4 FY2022Dec 31, 2022$164.84K–
Q3 FY2022Sep 30, 2022$314.89K–
Q2 FY2022Jun 30, 2022$321.71K–
Q1 FY2022Mar 31, 2022$187.61K–
Q3 FY2016Sep 30, 2016$0–

More Provectus Biopharmaceuticals figures

See a number that looks wrong?